Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 4/2012

Open Access 01-08-2012 | Research article

Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis

Authors: Annie Lauzier, Martine Charbonneau, Marilène Paquette, Kelly Harper, Claire M Dubois

Published in: Arthritis Research & Therapy | Issue 4/2012

Login to get access

Abstract

Introduction

The microenvironment surrounding inflamed synovium leads to the activation of fibroblast-like synoviocytes (FLSs), which are important contributors to cartilage destruction in rheumatoid arthritic (RA) joints. Transglutaminase 2 (TG2), an enzyme involved in extracellular matrix (ECM) cross-linking and remodeling, is activated by inflammatory signals. This study was undertaken to assess the potential contribution of TG2 to FLS-induced cartilage degradation.

Methods

Transglutaminase (TGase) activity and collagen degradation were assessed with the immunohistochemistry of control, collagen-induced arthritic (CIA) or TG2 knockdown (shRNA)-treated joint tissues. TGase activity in control (C-FLS) and arthritic (A-FLS) rat FLSs was measured by in situ 5-(biotinamido)-pentylamine incorporation. Invadopodia formation and functions were measured in rat FLSs and cells from normal (control; C-FLS) and RA patients (RA-FLS) by in situ ECM degradation. Immunoblotting, enzyme-linked immunosorbent assay (ELISA), and p3TP-Lux reporter assays were used to assess transforming growth factor-β (TGF-β) production and activation.

Results

TG2 and TGase activity were associated with cartilage degradation in CIA joints. In contrast, TGase activity and cartilage degradation were reduced in joints by TG2 knockdown. A-FLSs displayed higher TGase activity and TG2 expression in ECM than did C-FLSs. TG2 knockdown or TGase inhibition resulted in reduced invadopodia formation in rat and human arthritic FLSs. In contrast, increased invadopodia formation was noted in response to TGase activity induced by TGF-β, dithiothreitol (DTT), or TG2 overexpression. TG2-induced increases in invadopodia formation were blocked by TGF-β neutralization or inhibition of TGF-βR1.

Conclusions

TG2, through its TGase activity, is required for ECM degradation in arthritic FLS and CIA joints. Our findings provide a potential target to prevent cartilage degradation in RA.
Appendix
Available only for authorised users
Literature
1.
Noss EH, Brenner MB: The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev. 2008, 223: 252-270. 10.1111/j.1600-065X.2008.00648.x.CrossRefPubMed
2.
Nanki T, Nagasaka K, Hayashida K, Saita Y, Miyasaka N: Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol. 2001, 167: 5381-5385.CrossRefPubMed
3.
Nakahara H, Song J, Sugimoto M, Hagihara K, Kishimoto T, Yoshizaki K, Nishimoto N: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003, 48: 1521-1529. 10.1002/art.11143.CrossRefPubMed
4.
Garcia-Vicuna R, Gomez-Gaviro MV, Dominguez-Luis MJ, Pec MK, Gonzalez-Alvaro I, Alvaro-Gracia JM, Diaz-Gonzalez F: CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients. Arthritis Rheum. 2004, 50: 3866-3877. 10.1002/art.20615.CrossRefPubMed
5.
Remmers EF, Lafyatis R, Kumkumian GK, Case JP, Roberts AB, Sporn MB, Wilder RL: Cytokines and growth regulation of synoviocytes from patients with rheumatoid arthritis and rats with streptococcal cell wall arthritis. Growth Factors. 1990, 2: 179-188.PubMed
6.
Barilla ML, Carsons SE: Fibronectin fragments and their role in inflammatory arthritis. Semin Arthritis Rheum. 2000, 29: 252-265. 10.1016/S0049-0172(00)80012-8.CrossRefPubMed
7.
Sundblad L, Egelius N, Jonsson E: Action of hydrocortisone on the hyaluronic acid of joint fluids in rheumatoid arthritis. Scand J Clin Lab Invest. 1954, 6: 295-302. 10.3109/00365515409134867.CrossRefPubMed
8.
Jackson JR, Minton JA, Ho ML, Wei N, Winkler JD: Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 1beta. J Rheumatol. 1997, 24: 1253-1259.PubMed
9.
Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol. 1996, 149: 1607-1615.PubMedCentralPubMed
10.
Linder S: The matrix corroded: podosomes and invadopodia in extracellular matrix degradation. Trends Cell Biol. 2007, 17: 107-117. 10.1016/j.tcb.2007.01.002.CrossRefPubMed
11.
Lauzier A, Charbonneau M, Harper K, Jilaveanu-Pelmus M, Dubois CM: Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in collagen-induced arthritis: involvement of the protein tyrosine kinase Src. Arthritis Rheum. 2011, 63: 1591-1602. 10.1002/art.30305.CrossRefPubMed
12.
13.
Mehta K, Han A: Tissue transglutaminase (TG2)-induced inflammation in initiation, progression, and pathogenesis of pancreatic cancer. Cancers. 2011, 3: 897-912. 10.3390/cancers3010897.PubMedCentralCrossRefPubMed
14.
Griffin M, Wilson J: Detection of epsilon(gamma-glutamyl) lysine. Mol Cell Biochem. 1984, 58: 37-49. 10.1007/BF00240603.CrossRefPubMed
15.
Hasegawa G, Suwa M, Ichikawa Y, Ohtsuka T, Kumagai S, Kikuchi M, Sato Y, Saito Y: A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J. 2003, 373: 793-803. 10.1042/BJ20021084.PubMedCentralCrossRefPubMed
16.
Mishra S, Murphy LJ: Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem. 2004, 279: 23863-23868. 10.1074/jbc.M311919200.CrossRefPubMed
17.
Nakaoka H, Perez DM, Baek KJ, Das T, Husain A, Misono K, Im MJ, Graham RM: Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science. 1994, 264: 1593-1596. 10.1126/science.7911253.CrossRefPubMed
18.
Akimov SS, Krylov D, Fleischman LF, Belkin AM: Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol. 2000, 148: 825-838. 10.1083/jcb.148.4.825.PubMedCentralCrossRefPubMed
19.
Akimov SS, Belkin AM: Cell surface tissue transglutaminase is involved in adhesion and migration of monocytic cells on fibronectin. Blood. 2001, 98: 1567-1576. 10.1182/blood.V98.5.1567.CrossRefPubMed
20.
Verderio EA, Telci D, Okoye A, Melino G, Griffin M: A novel RGD-independent cell adhesion pathway mediated by fibronectin-bound tissue transglutaminase rescues cells from anoikis. J Biol Chem. 2003, 278: 42604-42614. 10.1074/jbc.M303303200.CrossRefPubMed
21.
Ritter SJ, Davies PJ: Identification of a transforming growth factor-beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element within the mouse tissue transglutaminase gene promoter. J Biol Chem. 1998, 273: 12798-12806. 10.1074/jbc.273.21.12798.CrossRefPubMed
22.
Telci D, Collighan RJ, Basaga H, Griffin M: Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide. J Biol Chem. 2009, 284: 29547-29558. 10.1074/jbc.M109.041806.PubMedCentralCrossRefPubMed
23.
Kuncio GS, Tsyganskaya M, Zhu J, Liu SL, Nagy L, Thomazy V, Davies PJ, Zern MA: TNF-alpha modulates expression of the tissue transglutaminase gene in liver cells. Am J Physiol. 1998, 274: G240-G245.PubMed
24.
Johnson K, Hashimoto S, Lotz M, Pritzker K, Terkeltaub R: Interleukin-1 induces pro-mineralizing activity of cartilage tissue transglutaminase and factor XIIIa. Am J Pathol. 2001, 159: 149-163. 10.1016/S0002-9440(10)61682-3.PubMedCentralCrossRefPubMed
25.
Mehta K, Kumar A, Kim HI: Transglutaminase 2: a multi-tasking protein in the complex circuitry of inflammation and cancer. Biochem Pharmacol. 2010, 80: 1921-1929. 10.1016/j.bcp.2010.06.029.CrossRefPubMed
26.
Orlandi A, Oliva F, Taurisano G, Candi E, Di Lascio A, Melino G, Spagnoli LG, Tarantino U: Transglutaminase-2 differently regulates cartilage destruction and osteophyte formation in a surgical model of osteoarthritis. Amino Acids. 2009, 36: 755-763. 10.1007/s00726-008-0129-3.CrossRefPubMed
27.
Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E: Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol. 2007, 124: 244-257. 10.1016/j.clim.2007.03.543.CrossRefPubMed
28.
Pham NA, Morrison A, Schwock J, Aviel-Ronen S, Iakovlev V, Tsao MS, Ho J, Hedley DW: Quantitative image analysis of immunohistochemical stains using a CMYK color model. Diagn Pathol. 2007, 2: 8-10.1186/1746-1596-2-8.PubMedCentralCrossRefPubMed
29.
Charbonneau M, Harper K, Grondin F, Pelmus M, McDonald PP, Dubois CM: Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor alpha-induced increases in tumor necrosis factor-alpha converting enzyme/ADAM17 expression by synovial cells. J Biol Chem. 2007, 282: 33714-33724. 10.1074/jbc.M704041200.CrossRefPubMed
30.
Baldassarre M, Ayala I, Beznoussenko G, Giacchetti G, Machesky LM, Luini A, Buccione R: Actin dynamics at sites of extracellular matrix degradation. Eur J Cell Biol. 2006, 85: 1217-1231. 10.1016/j.ejcb.2006.08.003.CrossRefPubMed
31.
Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, Coppolino MG: VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci. 2009, 122: 4089-4098. 10.1242/jcs.052761.CrossRefPubMed
32.
Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, Wang XF, Massague J: TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992, 71: 1003-1014. 10.1016/0092-8674(92)90395-S.CrossRefPubMed
33.
Yuan L, Choi K, Khosla C, Zheng X, Higashikubo R, Chicoine MR, Rich KM: Tissue transglutaminase 2 inhibition promotes cell death and chemosensitivity in glioblastomas. Mol Cancer Ther. 2005, 4: 1293-1302. 10.1158/1535-7163.MCT-04-0328.CrossRefPubMed
34.
McConoughey SJ, Basso M, Niatsetskaya ZV, Sleiman SF, Smirnova NA, Langley BC, Mahishi L, Cooper AJ, Antonyak MA, Cerione RA, Li B, Starkov A, Chaturvedi RK, Beal MF, Coppola G, Geschwind DH, Ryu H, Xia L, Iismaa SE, Pallos J, Pasternack R, Hils M, Fan J, Raymond LA, Marsh JL, Thompson LM, Ratan RR: Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med. 2010, 2: 349-370. 10.1002/emmm.201000084.PubMedCentralCrossRefPubMed
35.
Wolf K, Friedl P: Functional imaging of pericellular proteolysis in cancer cell invasion. Biochimie. 2005, 87: 315-320. 10.1016/j.biochi.2004.10.016.CrossRefPubMed
36.
Summey BT, Graff RD, Lai TS, Greenberg CS, Lee GM: Tissue transglutaminase localization and activity regulation in the extracellular matrix of articular cartilage. J Orthop Res. 2002, 20: 76-82. 10.1016/S0736-0266(01)00064-X.CrossRefPubMed
37.
Artym VV, Zhang Y, Seillier-Moiseiwitsch F, Yamada KM, Mueller SC: Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function. Cancer Res. 2006, 66: 3034-3043. 10.1158/0008-5472.CAN-05-2177.CrossRefPubMed
38.
George MD, Vollberg TM, Floyd EE, Stein JP, Jetten AM: Regulation of transglutaminase type II by transforming growth factor-beta 1 in normal and transformed human epidermal keratinocytes. J Biol Chem. 1990, 265: 11098-11104.PubMed
39.
Pinkas DM, Strop P, Brunger AT, Khosla C: Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol. 2007, 5: e327-10.1371/journal.pbio.0050327.PubMedCentralCrossRefPubMed
40.
Siegel M, Khosla C: Transglutaminase 2 inhibitors and their therapeutic role in disease states. Pharmacol Ther. 2007, 115: 232-245. 10.1016/j.pharmthera.2007.05.003.PubMedCentralCrossRefPubMed
41.
Verderio E, Gaudry C, Gross S, Smith C, Downes S, Griffin M: Regulation of cell surface tissue transglutaminase: effects on matrix storage of latent transforming growth factor-beta binding protein-1. J Histochem Cytochem. 1999, 47: 1417-1432. 10.1177/002215549904701108.CrossRefPubMed
42.
Tarantino U, Ferlosio A, Arcuri G, Spagnoli LG, Orlandi A: Transglutaminase 2 as a biomarker of osteoarthritis: an update. Amino Acids. 2011
43.
Weinberg JB, Pippen AM, Greenberg CS: Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 1991, 34: 996-1005. 10.1002/art.1780340809.CrossRefPubMed
44.
Stenberg P, Roth B, Wollheim FA: Peptidylarginine deiminases and the pathogenesis of rheumatoid arthritis: a reflection of the involvement of transglutaminase in coeliac disease. Eur J Intern Med. 2009, 20: 749-755. 10.1016/j.ejim.2009.08.007.CrossRefPubMed
45.
Dzhambazov B, Lindh I, Engstrom A, Holmdahl R: Tissue transglutaminase enhances collagen type II-induced arthritis and modifies the immunodominant T-cell epitope CII260-270. Eur J Immunol. 2009, 39: 2412-2423. 10.1002/eji.200939438.CrossRefPubMed
46.
Bartok B, Firestein GS: Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010, 233: 233-255. 10.1111/j.0105-2896.2009.00859.x.PubMedCentralCrossRefPubMed
47.
Shiozawa S, Yoshihara R, Kuroki Y, Fujita T, Shiozawa K, Imura S: Pathogenic importance of fibronectin in the superficial region of articular cartilage as a local factor for the induction of pannus extension on rheumatoid articular cartilage. Ann Rheum Dis. 1992, 51: 869-873. 10.1136/ard.51.7.869.PubMedCentralCrossRefPubMed
48.
Yuan L, Siegel M, Choi K, Khosla C, Miller CR, Jackson EN, Piwnica-Worms D, Rich KM: Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene. 2007, 26: 2563-2573. 10.1038/sj.onc.1210048.CrossRefPubMed
49.
Forsprecher J, Wang Z, Nelea V, Kaartinen MT: Enhanced osteoblast adhesion on transglutaminase 2-crosslinked fibronectin. Amino Acids. 2009, 36: 747-753. 10.1007/s00726-008-0125-7.CrossRefPubMed
50.
Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D: Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012, 31: 2521-2534. 10.1038/onc.2011.429.CrossRefPubMed
51.
Ruan Q, Johnson GV: Transglutaminase 2 in neurodegenerative disorders. Front Biosci. 2007, 12: 891-904. 10.2741/2111.CrossRefPubMed
52.
De Vivo G, Di Lorenzo R, Ricotta M, Gentile V: Role of the transglutaminase enzymes in the nervous system and their possible involvement in neurodegenerative diseases. Curr Med Chem. 2009, 16: 4767-4773. 10.2174/092986709789909594.CrossRefPubMed
53.
Huang L, Haylor JL, Fisher M, Hau Z, El Nahas AM, Griffin M, Johnson TS: Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy?. Nephrol Dial Transplant. 2010, 25: 3897-3910. 10.1093/ndt/gfq291.CrossRefPubMed
54.
Kumar A, Xu J, Brady S, Gao H, Yu D, Reuben J, Mehta K: Tissue transglutaminase promotes drug resistance and invasion by inducing mesenchymal transition in mammary epithelial cells. PLoS One. 2010, 5: e13390-10.1371/journal.pone.0013390.PubMedCentralCrossRefPubMed
55.
Shweke N, Boulos N, Jouanneau C, Vandermeersch S, Melino G, Dussaule JC, Chatziantoniou C, Ronco P, Boffa JJ: Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am J Pathol. 2008, 173: 631-642. 10.2353/ajpath.2008.080025.PubMedCentralCrossRefPubMed
56.
Nunes I, Gleizes PE, Metz CN, Rifkin DB: Latent transforming growth factor-beta binding protein domains involved in activation and transglutaminase-dependent cross-linking of latent transforming growth factor-beta. J Cell Biol. 1997, 136: 1151-1163. 10.1083/jcb.136.5.1151.PubMedCentralCrossRefPubMed
57.
Telci D, Wang Z, Li X, Verderio EA, Humphries MJ, Baccarini M, Basaga H, Griffin M: Fibronectin-tissue transglutaminase matrix rescues RGD-impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. J Biol Chem. 2008, 283: 20937-20947. 10.1074/jbc.M801763200.PubMedCentralCrossRefPubMed
58.
Mandal S, Johnson KR, Wheelock MJ: TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways. Exp Cell Res. 2008, 314: 3478-3493. 10.1016/j.yexcr.2008.09.013.CrossRefPubMed
59.
Buccione R, Caldieri G, Ayala I: Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev. 2009, 28: 137-149. 10.1007/s10555-008-9176-1.CrossRefPubMed
60.
Salliot C, Dougados M, Gossec L: Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009, 68: 25-32.PubMedCentralCrossRefPubMed
61.
Junn E, Ronchetti RD, Quezado MM, Kim SY, Mouradian MM: Tissue transglutaminase-induced aggregation of alpha-synuclein: implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA. 2003, 100: 2047-2052. 10.1073/pnas.0438021100.PubMedCentralCrossRefPubMed
62.
Wilhelmus MM, van Dam AM, Drukarch B: Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases. Eur J Pharmacol. 2008, 585: 464-472. 10.1016/j.ejphar.2008.01.059.CrossRefPubMed
63.
Elli L, Ciulla MM, Busca G, Roncoroni L, Maioli C, Ferrero S, Bardella MT, Bonura A, Paliotti R, Terrani C, Braidotti P: Beneficial effects of treatment with transglutaminase inhibitor cystamine on the severity of inflammation in a rat model of inflammatory bowel disease. Lab Invest. 2011, 91: 452-461. 10.1038/labinvest.2010.186.CrossRefPubMed
64.
Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S: Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation. J Immunol. 2008, 180: 7697-7705.CrossRefPubMed
65.
Oh K, Park HB, Byoun OJ, Shin DM, Jeong EM, Kim YW, Kim YS, Melino G, Kim IG, Lee DS: Epithelial transglutaminase 2 is needed for T cell interleukin-17 production and subsequent pulmonary inflammation and fibrosis in bleomycin-treated mice. J Exp Med. 2011, 208: 1707-1719. 10.1084/jem.20101457.PubMedCentralCrossRefPubMed
66.
Johnson TS, Fisher M, Haylor JL, Hau Z, Skill NJ, Jones R, Saint R, Coutts I, Vickers ME, El Nahas AM, Griffin M: Transglutaminase inhibition reduces fibrosis and preserves function in experimental chronic kidney disease. J Am Soc Nephrol. 2007, 18: 3078-3088. 10.1681/ASN.2006070690.CrossRefPubMed
67.
Sohn J, Chae JB, Lee SY, Kim SY, Kim JG: A novel therapeutic target in inflammatory uveitis: transglutaminase 2 inhibitor. Korean J Ophthalmol. 2010, 24: 29-34. 10.3341/kjo.2010.24.1.29.PubMedCentralCrossRefPubMed
Metadata
Title
Transglutaminase 2 cross-linking activity is linked to invadopodia formation and cartilage breakdown in arthritis
Authors
Annie Lauzier
Martine Charbonneau
Marilène Paquette
Kelly Harper
Claire M Dubois
Publication date
01-08-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 4/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3899

Other articles of this Issue 4/2012

Arthritis Research & Therapy 4/2012 Go to the issue

Review

Platelet-rich plasma therapy - future or trend?

Research article

Early systemic sclerosis: short-term disease evolution and factors predicting the development of new manifestations of organ involvement

Research article

A novel autoantibody against fibronectin leucine-rich transmembrane protein 2 expressed on the endothelial cell surface identified by retroviral vector system in systemic lupus erythematosus

Research article

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis

Research article

Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis

Erratum

Erratum to: Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits